Convergent Dental announces FDA clearance of osseous tissue procedures for Solea at ADA 2015
Convergent Dental is showcasing Solea at ADA 2015 in Washington, D.C. from November 5-10, 2015.
Convergent Dental, Inc., a privately held dental device company, announced Solea®, the first FDA-cleared CO2 9.3-micron dental laser for hard and soft tissue, has also been cleared to perform osseous tissue procedures.
With this expanded indication, Solea reportedly can be used to treat not only cavity preparations and soft-tissue surgery but also bone cutting, shaving, recontouring and resection. Convergent Dental is showcasing Solea at ADA 2015 in Washington, D.C. from November 5-10, 2015.
Solea’s osseous tissue clearance is said to allow dentists to perform procedures ablating bone with speed, precision and less bleeding. As a result, patients may experience less post-operative discomfort and faster healing times. These benefits are designed to improve the patient experience, reduce chairtime and increase the economic impact for a dental practice.
“Convergent Dental’s rapidly expanding clinical indications for Solea is another example of their commitment to innovation,” Dr. Simon Bernstein said. “With this new osseous tissue clearance by the FDA, Solea’s unique 9.3-micron wavelength continues to create the opportunity for minimally invasive dentistry.”
“This osseous tissue clearance is a critical component of our long term grow strategy. It adds even greater value for our current customers who can add more procedures to their repertoire and makes Solea a compelling option for specialists including periodontists and oral surgeons,” Convergent Dental CEO Michael Cataldo said.
Convergent Dental ‘s focus on continuous innovation has made it the fastest growing all-tissue dental laser company in the United States. Practitioners interested in learning more about Solea and its latest FDA clearance for osseous tissue procedures can email [email protected] or call 1-844-GO-SOLEA.